Genprex

Category: Press Releases

Genprex Bolsters Board of Directors, Appoints Three Biotechnology and Healthcare Industry Leaders

These board additions will enhance the Company’s ability to execute on key corporate initiatives.

Read More

Genprex Strengthens Leadership Team with the Appointment of Two Accomplished Life Science Executives

These seasoned industry professionals combined with the company’s newly strengthened balance sheet will drive key clinical programs.

Read More

Lead Researcher Behind Genprex’s Diabetes Gene Therapy Featured in New Video Interview

Dr. George Gittes, the lead researcher and Harvard graduate that developed Genprex’s new potentially curative diabetes gene therapy, was featured in a video interview discussing the therapy.

Read More

Genprex to Present at the 2020 LD Micro Virtual Conference

Genprex will present at the third annual LD Micro Virtual Conference on Wednesday, March 4 at 1:40 p.m. EST. Genprex’s Chairman and Chief Executive Officer, Rodney Varner, will lead the company’s presentation and will be answering questions from investors.

Read More

Genprex, Inc. Announces Closing of $17,500,000 Common Stock Offering At-The-Market and Without Warrants

The Company intends to use the net proceeds from the offering to advance its drug development programs and for working capital and general corporate purposes.

Read More

Genprex, Inc. Prices $17,500,000 Common Stock Offering Priced At-The-Market and Without Warrants

The closing of the registered direct offering is expected to take place on or about February 21, 2020, subject to the satisfaction of customary closing conditions.

Read More

Genprex and University of Pittsburgh Sign Exclusive License Agreement for Potentially Curative Gene Therapy Candidate for Diabetes

Genprex signed an exclusive license agreement with the University of Pittsburgh for a diabetes gene therapy that may have the potential to cure Type 1 and Type 2 diabetes, which together currently affect approximately 30.3 million people in the U.S, or 9 percent of the U.S. population.

Read More

Genprex Regains Compliance with Nasdaq Minimum Bid Price Requirement

Genprex announced that it received notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule.

Read More

Genprex to Focus Its Clinical Efforts on Oncoprex™ in Combination Therapy with Osimertinib for Non-Small Cell Lung Cancer (NSCLC)

Genprex provides a clinical update and focus for its Oncoprex™ immunogene therapy program for 2020, prioritizing the development of Oncoprex in combination with osimertinib for the treatment of non-small cell lung cancer (NSCLC).

Read More

Genprex to Present at NobleCon16 Investor Conference

Mr. Rodney Varner, Chief Executive Officer of Genprex, will deliver an overview of the Company and provide updates on its product pipeline, including the recent Fast Track Designation received from the Food and Drug Administration for its Oncoprex™ immunogene therapy in combination with AstraZeneca’s Tagrisso®.

Read More